Development and Validation of the novel Cuproptosis- and Immune-related Signature for Predicting Prognosis in Hepatocellular Carcinoma
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces a new prognostic model for Hepatocellular carcinoma (HCC) by combining cuproptosis and immune cell data. This model helps identify high-risk patients and may guide personalized treatments.
Area Of Science
- Oncology
- Molecular Biology
- Bioinformatics
Background
- Hepatocellular carcinoma (HCC) diagnosis is often delayed, reducing treatment efficacy.
- Prognosis for HCC patients can be improved by integrating novel molecular pathways and immune markers.
Purpose Of The Study
- To develop and validate a prognostic biomarker integrating cuproptosis and immune responses for Hepatocellular carcinoma.
- To identify key genes associated with cuproptosis and immunity for risk stratification in HCC patients.
Main Methods
- Differential gene expression analysis between cuproptosis and immune responses.
- Construction and validation of a risk signature using LASSO regression and the International Cancer Genome Consortium (ICGC) dataset.
- Quantitative PCR (qPCR) and western blotting to validate bioinformatics findings.
Main Results
- Eight key genes were identified as prognostic markers for HCC.
- A validated risk-scoring model effectively stratified patients into low- and high-risk groups with distinct survival outcomes.
- The risk signature demonstrated independent predictive capability and informed potential benefits from immune checkpoint inhibitors.
Conclusions
- A novel genetic risk signature integrating cuproptosis and immunity shows promise as a prognostic biomarker for Hepatocellular carcinoma.
- This signature may facilitate personalized therapeutic strategies for HCC patients.

